Harmony Biosciences Holdings Inc
NASDAQ:HRMY
Harmony Biosciences Holdings Inc
NASDAQ:HRMY
Price:
27.72
USD
-0.32%
Market Closed
Market Cap:
$1.6B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Harmony Biosciences Holdings Inc
NASDAQ:HRMY
|
US |
|
S
|
ScandBook Holding AB
STO:SBOK
|
SE |
|
SKY Perfect JSAT Holdings Inc
TSE:9412
|
JP |
|
P
|
Punit Commercials Ltd
BSE:512099
|
IN |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
US |
|
Wanhua Chemical Group Co Ltd
SSE:600309
|
CN |
|
China Ecotek Corp
TWSE:1535
|
TW |
|
T
|
Titan America SA
NYSE:TTAM
|
BE |
|
Auxico Resources Canada Inc
OTC:AUXIF
|
CA |
|
Keppel REIT
SGX:K71U
|
SG |
|
Packaging Corp of America
NYSE:PKG
|
US |
|
P
|
Partner Communications Company Ltd
TASE:PTNR
|
IL |
|
Stoneridge Inc
NYSE:SRI
|
US |
Relative Value
The Relative Value of one
HRMY
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 27.72 USD,
Harmony Biosciences Holdings Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HRMY Relative Value
HIDDEN
Multiples Across Competitors
HRMY Competitors Multiples
Harmony Biosciences Holdings Inc Competitors
Harmony Biosciences Holdings Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Harmony Biosciences Holdings Inc
NASDAQ:HRMY
|
1.6B USD | 1.8 | 10.1 | 4.2 | 4.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
856.7B USD | 13.1 | 41.5 | 28 | 29.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
566.8B USD | 6 | 21.1 | 14.7 | 18.1 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
243.3B CHF | 4 | 18.9 | 11.2 | 12.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 4.9 | 28.3 | 15.7 | 22.2 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
282.6B USD | 4.3 | 15.5 | 9.6 | 11.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
222.2B CHF | 5.1 | 20.5 | 12.7 | 16.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.4B USD | 2.5 | 19.7 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.7B USD | 2.4 | 16.4 | 7 | 8.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
